首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3366401篇
  免费   245620篇
  国内免费   8408篇
耳鼻咽喉   45358篇
儿科学   110956篇
妇产科学   94164篇
基础医学   479360篇
口腔科学   93838篇
临床医学   310761篇
内科学   657785篇
皮肤病学   78958篇
神经病学   276014篇
特种医学   128722篇
外国民族医学   965篇
外科学   496220篇
综合类   69087篇
现状与发展   7篇
一般理论   1448篇
预防医学   265910篇
眼科学   75918篇
药学   246103篇
  12篇
中国医学   6465篇
肿瘤学   182378篇
  2019年   26462篇
  2018年   36800篇
  2017年   28363篇
  2016年   32428篇
  2015年   36863篇
  2014年   50761篇
  2013年   76977篇
  2012年   102416篇
  2011年   108635篇
  2010年   65056篇
  2009年   62521篇
  2008年   102021篇
  2007年   108534篇
  2006年   109735篇
  2005年   105858篇
  2004年   101880篇
  2003年   98207篇
  2002年   94889篇
  2001年   156347篇
  2000年   160006篇
  1999年   135148篇
  1998年   39172篇
  1997年   34985篇
  1996年   35444篇
  1995年   34097篇
  1994年   31434篇
  1993年   29484篇
  1992年   106280篇
  1991年   103159篇
  1990年   99948篇
  1989年   96472篇
  1988年   88972篇
  1987年   87192篇
  1986年   82196篇
  1985年   78332篇
  1984年   58932篇
  1983年   50267篇
  1982年   29985篇
  1981年   26952篇
  1979年   53057篇
  1978年   37976篇
  1977年   32228篇
  1976年   29800篇
  1975年   31910篇
  1974年   38029篇
  1973年   36683篇
  1972年   34526篇
  1971年   32103篇
  1970年   29871篇
  1969年   28509篇
排序方式: 共有10000条查询结果,搜索用时 227 毫秒
61.
62.
Introduction: In men, lower urinary tract symptoms (LUTS) are primarily attributed to benign prostatic hyperplasia (BPH). Therapeutic options are targeted to relax prostate smooth muscle and/or reduce prostate enlargement.

Areas covered: This article reviews the major preclinical and clinical data on PDE5 inhibitors with a specific focus on tadalafil. It includes details of the role of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) – PDE5 pathway in the LUT organs (bladder and prostate) in addition to the available data on tadalafil in patients with LUTS secondary to BPH with or without erectile dysfunction (ED).

Expert opinion: Preclinical and clinical data have clearly demonstrated that PDE5 inhibitors induce bladder and prostate relaxation, which contributes to the improvement seen in storage symptoms in both animal models of bladder and prostate hypercontractility. Tadalafil is effective both as a monotherapy and add-on therapy in patients with LUTS secondary to BPH. Furthermore, as LUTS-BPH and ED are urological disorders that commonly coexist in aging men, tadalafil is more advantageous than α1-adrenoceptors and should be used as the first option. Tadalafil is a safe and tolerable therapy and unlike α1- adrenoceptors and 5-alpha reductase inhibitors, which can cause sexual dysfunctions, tadalafil improves sexual function.  相似文献   

63.
64.
65.
Academic output is just one aspect of a successful career as a plastic surgeon. However, for those with a strong interest in academia, the academic output of a department will likely be a key factor when deciding how to rank jobs. The aim of this study was to quantify and rank the academic output of plastic surgery units across the UK and Ireland. The Institute for Scientific Information (ISI) Web of Science Bibliometric analysis tool was used to collate cumulative (1950–2016), 10 year (2006–2016) and 3 years (2013–2015) research output data for plastic surgery units in the UK and Ireland. Sixty-six plastic surgery units were identified. Departments were ranked for each time period according to the number of papers produced, number of citations (Nc) and h-index (a measure of the impact of scientific output). The top 3 departments for number of papers in the last 10 years were The Royal Free Hospital, London (226) Broomfield Hospital, Chelmsford (218), and Morriston Hospital and Swansea (188). The top 3 for h-number were The Royal Free Hospital (21) Wythenshawe Hospital, Manchester (18) and Morriston Hospital (17). Academic output varies across plastic surgery units in the UK and Ireland. A number of departments have consistently maintained high academic outputs across the years and will be of interest to surgeons hoping to pursue a career in academia.  相似文献   
66.
67.
68.
Pharmaceutical Chemistry Journal - An HPLC-MS method for simultaneous quantitative determination of a novel gestagenic pharmaceutical and two of its metabolites in rat and rabbit blood sera was...  相似文献   
69.

Purpose

Endovascular treatment with mechanical thrombectomy devices demonstrated high recanalization rates but functional outcome did not correlate with high rates of recanalization obtained. Patient selection prior to the endovascular treatment is very important in the final outcome of the patient. The primary aim of our study was to evaluate the prognostic value of posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS) and Pons-Midbrain Index (PMI) scores in patients with Basilar Artery Occlusion (BAO) treated with successful angiographic recanalization after mechanical thrombectomy.

Methods

Retrospective single-center study including 18 patients between 2008 and 2013 who had acute basilar artery occlusion managed with endovascular treatment within 24 hours from symptoms onset and with successful angiographic recanalization. The patients were initially classified into two groups according to clinical outcome and mortality at 90 days. For analysis we also divided patients into groups based on pc-ASPECTS (≥8vs.< 8) and PMI (≥3vs.< 3) on non-contrast CT (NCCT) and CT Angiography Source Images (CTASI). Imaging data were correlated to clinical outcome and mortality rate.

Results

CTASI pc-ASPECTS, dichotomized at < 8 versus≥8, was associated with a favorable outcome (RR: 2.6; 95% CI: 1.3-5.2) and a reduced risk of death (RR: 6.5: 95% CI: 7.8-23.3). All patients that survived and were functionally independent had pc-ASPECTS score≥8. None of the 5 patients with CTASI pc-ASPECTS score less than 8 survived.

Conclusion

PC-ASPECTS on CTASI is helpful for predicting functional outcome after BAO recanalization with endovascular treatment. These results should be validated in a randomized controlled trial in order to decide whether or not to treat a patient with BAO.  相似文献   
70.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号